USE OF β-BLOCKERS IN MEDICARE BENEFICIARIES WITH SYSTOLIC HEART FAILURE AND HYPOTENSION, ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE OR PERIPHERAL VASCULAR DISEASE  by Levitan, Emily et al.
Heart Failure and Cardiomyopathies
A870
JACC March 17, 2015
Volume 65, Issue 10S
use of β-Blockers In medIcAre BenefIcIArIes wIth systolIc heArt fAIlure And 
hyPotensIon, AsthmA, chronIc oBstructIve PulmonAry dIseAse or PerIPherAl 
vAsculAr dIseAse
Poster Contributions
Poster Hall B1
Saturday, March 14, 2015, 3:45 p.m.-4:30 p.m.
Session Title: Advances in Heart Failure Therapies: From Diuretics to VADs and Transplant
Abstract Category: 14.  Heart Failure and Cardiomyopathies: Clinical
Presentation Number: 1146-200
Authors: Emily Levitan, Melissa K. Van Dyke, Ligong Chen, Monika Safford, Meredith Kilgore, University of Alabama at Birmingham, 
Birmingham, AL, USA, Amgen Inc, Thousand Oaks, CA, USA
Background:  Metoprolol succinate, bisoprolol and carvedilol (evidence-based β-blockers) improve outcomes in systolic heart failure (HF). 
However, conditions such as hypotension, asthma, chronic obstructive pulmonary disease (COPD) and peripheral vascular disease (PVD) 
may limit their use.
methods:  We identified hospitalizations for systolic HF (International Classification of Diseases-9 primary discharge diagnosis 428.2x or 
428.4x) in the Medicare national 5% sample. Insurance claims were used to assess characteristics in the year prior to hospitalization and 
β-blockers in the year following discharge. We used generalized estimating equations to calculate multi-variable adjusted risk ratios for use 
of β-blockers and evidence-based β-blockers.
results:  Out of 20,358 hospitalizations, there were claims for any β-blockers for 59.6% and evidence-based β-blockers for 44.9% in 
the year following discharge. Hypotension, asthma, COPD and PVD were common and were associated with less use of β-blockers 
and evidence-based β-blockers. Asthma, COPD and having ≥ 1 of the conditions remained significantly associated with less use of 
β-blockers after multivariable adjustment. Fewer than 20% used at least half of the maximum dose overall; this percentage was lower with 
hypotension, COPD, PVD or ≥ 1 of the conditions.
conclusion:  Although evidence-based β-blockers are efficacious treatments for systolic HF, their use is limited in practice and 
comorbidities and hypotension may further limit use.
Table. Use of beta-blockers following hospitalization for HF with systolic dysfunction, with and without hypotension, asthma, COPD and PVD
With condition Without condition
Hypotension, n 5,173 15,185
β-blockers, % 53.1% 61.9%
RR (95% CI) for β-blockers 0.97 (0.89, 1.05) Reference
Evidence-based β-blockers, % 41.1% 46.1%
RR (95% CI) for evidence-based β-blockers 1.09 (1.00, 1.19) Reference
≥50% maximum dose evidence-based β-blockers 13.0% 17.8%
Asthma, n 3,793 16,565
β-blockers, % 56.7% 60.3%
RR (95% CI) for β-blockers 0.87 (0.79, 0.95) Reference
Evidence-based β-blockers, % 43.6% 45.2%
RR (95% CI) for evidence-based β-blockers 0.94 (0.85, 1.03) Reference
≥50% maximum dose evidence-based β-blockers 17.5% 16.6%
Chronic obstructive pulmonary disease, n 11,389 8,969
β-blockers, % 56.7% 63.4%
RR (95% CI) for β-blockers 0.89 (0.83, 0.95) Reference
Evidence-based β-blockers, % 43.0% 47.3%
RR (95% CI) for evidence-based β-blockers 0.97 (0.90, 1.04) Reference
≥50% maximum dose evidence-based β-blockers 16.4% 17.1%
Peripheral vascular disease, n 1,267 19,091
β-blockers, % 52.1% 60.1%
RR (95% CI) for β-blockers 0.90 (0.78, 1.03) Reference
Evidence-based β-blockers, % 38.9% 45.3%
RR (95% CI) for evidence-based β-blockers 0.90 (0.77, 1.05) Reference
≥50% maximum dose evidence-based β-blockers 15.9% 16.8%
≥ 1 of the conditions, n 14,268 6,090
β-blockers, % 56.7% 66.6%
RR (95% CI) for β-blockers 0.81 (0.75, 0.87) Reference
Evidence-based β-blockers, % 43.0% 49.3%
RR (95% CI) for evidence-based β-blockers 0.93 (0.86, 1.01) Reference
≥50% maximum dose evidence-based β-blockers 16.1% 18.0%
Risk ratios (RR) and 95% confidence intervals (CI) adjusted for demographics, comorbidities, healthcare utilization and hospitalization characteristics
